Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.43 |
| ▸ | FPR2 | P25090 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | CCR3 | P51677 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.40 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.39 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.39 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12396138 | 0.88 | CCR3 (0.44) | OPRM1FPR2DRD2CCR3LTA4H | |
| SCHEMBL12396183 | 0.87 | FPR2 (0.47) | OPRM1FPR2DRD2CCR3LTA4H | |
| SCHEMBL12396158 | 0.81 | FPR2 (0.46) | OPRM1FPR2DRD2CCR3LTA4H | |
| SCHEMBL12396199 | 0.81 | CCR3 (0.46) | CCR3KMT2ARAB9AMCHR1SMN1; SMN2 | |
| SCHEMBL12396148 | 0.81 | FPR2 (0.48) | OPRM1FPR2DRD2CCR3LTA4H | |
| SCHEMBL12396187 | 0.81 | FPR2 (0.53) | OPRM1FPR2DRD2CCR3LTA4H | |
| SCHEMBL12396194 | 0.81 | NPY5R (0.42) | OPRM1DRD2LTA4HMEN1KMT2A | |
| SCHEMBL12396202 | 0.81 | CCR3 (0.47) | FPR2CCR3MEN1KMT2ANPC1 | |
| SCHEMBL12396192 | 0.80 | CCR3 (0.45) | OPRM1FPR2DRD2CCR3LTA4H | |
| SCHEMBL12396178 | 0.80 | EPHX1 (0.44) | OPRM1DRD2CCR3MCHR1MCHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110183358-A1 | METHODS AND COMPOSITIONS FOR DEREPRESSION OF IAP-INHIBITED CASPASE | THE BURNHAM INSTITUTE (US) | 2011-07-28 | — | — | US | disclosed |
| US-7217688-B2 | Methods and compositions for derepression of IAP-inhibited caspase | THE BURNHAM INSTITUTE (US) | 2007-05-15 | — | — | US | disclosed |
| US-20070003535-A1 | Methods and compositions for derepression of IAP-inhibited caspase | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070003535-A1 | Methods and compositions for derepression of IAP-inhibited caspase | BIRC5, API5, BIRC3 | OPRM1 4782/4885FPR2 3403/4885DRD2 4019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.